Rymedi and Precision Genetics have entered a strategic alliance to combine Precision Genetics' PrecisionOp pharmacogenetics platform and Rymedi's blockchain-enabled health data management solutions  to enhance the efficiency of precision therapeutics.

As part of the collaboration, Rymedi's clinical trial and registry platform will support Precision Genetics' IRB-approved research study, Prospective Outcomes & Molecular Implementation Support Registry (PROMISRx), to track and analyze surgical patients’ responses to certain medications. The study is aimed to produce information that can be used to develop personalized therapeutics for optimal recovery and minimal side effects. 

Precision Genetics specializes in advanced molecular diagnostics and pharmacogenetic solutions aimed at developing personalized treatments. Its key products include testing services such as the PrecisionOp platform for perioperative care, Neuropharmagen mental health diagnostic solution, and Precision Primary for comprehensive health solutions, all of which use genetic insights to determine medication efficacy and safety​.